Man­u­fac­tur­ing roundup: Catal­ent to pro­duce low-cost ver­sion of nalox­one; CSL opens R&D site

Catal­ent will be man­u­fac­tur­ing a low-cost ver­sion of the opi­oid over­dose treat­ment nalox­one as part of a con­tract with Harm Re­duc­tion Ther­a­peu­tics.

Catal­ent plans to man­u­fac­ture the treat­ment at its fa­cil­i­ty in Mor­risville, NC. No fi­nan­cial de­tails on the deal were dis­closed.

Harm Re­duc­tion was grant­ed pri­or­i­ty re­view sta­tus for the NDA on its spray last year. The com­pa­ny has been work­ing on a nalox­one prod­uct since 2017. It is an­tic­i­pat­ing ap­proval in Ju­ly of this year and a US launch in ear­ly 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER